Imaginab, Inc.

UEI
NN7GWLY4L167
CAGE
58X66
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Expired

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Website
imaginab.com
Founded
2007
Employees
11-50
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Biotechnology
SIC code
87 Engineering & Management Services
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract awards

Award Agency Obligated Awarded
Engineered immunopet tracers for pancreatic cancer HHSN261201400047C National Cancer Institute (NIH) $164,934
Sbir topic 307 phase i novel imaging agents to expand the clinical toolkit for cancer diagnosis, staging, and treatment HHSN261201100120C National Cancer Institute (NIH) $224,264
Sbir topic 266 - phase II HHSN261201100123C National Cancer Institute (NIH) $1,000,000
Biomedical (basic) HHSN261200900051C National Cancer Institute (NIH) $199,363

Grant awards

Award Agency Obligated Awarded
Clinical development of a novel pet imaging agent for prostate cancer R44CA192927 National Cancer Institute (NIH) $1,000,000
Clinical production and IND enabling studies for psca minibody imaging in pancrea R44CA157025 National Institutes of Health $995,229

Quick answers

Is Imaginab, Inc. registered in SAM.gov?

Imaginab, Inc.'s SAM.gov registration expired on March 4, 2026.

What is Imaginab, Inc.'s most recent federal award?

Imaginab, Inc.'s most recent federal grant award is Clinical development of a novel pet imaging agent for prostate cancer (R44CA192927), from National Cancer Institute (NIH), on August 15, 2016.

On GovTribe

See Imaginab, Inc.'s full federal record

  • Federal contract awards
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login